Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Fig. 3

Association of ANK2 mutation with clinical outcomes in ICIs-treated LUAD cohort. A: Kaplan–Meier survival curves comparing PFS between the ANK2-MT and ANK2-WT LUAD in ICIs-treated cohort. B: Comparison of the proportion of patients with complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) between ANK2-MT and ANK2-WT LUAD in ICIs-treated cohort. C: Comparison of the proportion of patients with durable clinical benefit (DCB) or no durable benefit (NDB) between ANK2-MT and ANK2-WT LUAD in ICIs-treated cohort. D: Comparison of the TMB between ANK2-MT and ANK2-WT LUAD in ICIs-treated cohort. E: Comparison of the PNB between ANK2-MT and ANK2-WT LUAD in ICIs-treated cohort. F: The landscape of co-mutation between ANK2 and MMR pathway-related genes in LUAD. G: The landscape of co-mutation between ANK2 and DDR pathway-related genes in LUAD (NR, not reached; *P < 0.05, **P < 0.01, ****P < 0.0001)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us